Topic Amgen

Companies Amgen

News Amgen

• UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosis

  UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of Resear more

• Amgen and European Schoolnet Launch New Professional Development Initiative for Life Science Teachers

  The Amgen Foundation and European Schoolnet launched the "Amgen Science Teacher Training Initiative" in France, Germany, Ireland and Poland.The Amgen Science Teacher Training Initiative provides professional development for secondary school science teachers to help them incorporate hands-on enquiry- more

• Amgen to Acquire Micromet

  Amgen and Micromet, Inc.announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany, for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously more

White papers Amgen

• Frost & Sullivan's Global PharmAlliance 2005: Becoming the Partner of Choice
  

  Looking at the increasing trend towards partnerships and alliances in the pharmaceutical industry, Frost & Sullivan a global growth consulting company had organized a premium conference, "Global PharmAlliance 2005 - Becoming the partner of choice" in Mumbai (India). The two day event focused on giving an insight into the world of partnerships and alliances through... more

Publications Amgen

• Ligand Binding Assays in the 21st Century Laboratory: Automation

  Ligand Binding Assays in the 21st Century Laboratory: Automation Content Type Journal Article Category Commentary Pages 1-12 DOI 10.1208/s12248-012-9323-z Authors Ago B. Ahene, XOMA Corporation, 2710 Seventh Street, Berkeley, California 94710, USA Chris Morrow, Genentech, South San Fra more

• Ligand Binding Assays in the 21st Century Laboratory: Platforms

  Ligand Binding Assays in the 21st Century Laboratory: Platforms Content Type Journal Article Category Commentary Pages 1-6 DOI 10.1208/s12248-012-9321-1 Authors Franklin P. Spriggs, Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., 1 Burtt Road, MS G2002, Andover, more

• Ligand-Binding Assays in the 21st Century Laboratory: Recommendations for an Automated Data Interchange Process

  Ligand-Binding Assays in the 21st Century Laboratory: Recommendations for an Automated Data Interchange Process Content Type Journal Article Category Commentary Pages 1-8 DOI 10.1208/s12248-011-9319-0 Authors Sheldon S. Leung, Pfizer Inc., 1 Burtt Rd, Andover, Massachusetts 01810, USA more

Market studies Amgen

• Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Osteopenia Therapeutics market. The report identifies the more

• Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020”. The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provi more

• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014

  GBI Research, the leading business intelligence provider, has released its latest report, “Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014”. The report is built using data and information sourced from proprietary databas more

Websites Amgen